Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22828374 | 0.85 | STING1 (0.55) | RAB9ANPC1TRPV1MAPTNTRK1 | |
| SCHEMBL22828406 | 0.80 | KMT2A (0.62) | RAB9AMAPTNTRK1NTRK3MEN1 | |
| SCHEMBL22828671 | 0.79 | CLK2 (0.49) | RAB9ANPC1TRPV1DYRK1AMAPT | |
| SCHEMBL22828672 | 0.76 | DEGS1 (0.46) | RAB9AMAPTDEGS1NTRK1NTRK3 | |
| SCHEMBL23719252 | 0.76 | TP53 (0.52) | RAB9ANPC1GSK3BMAPTNTRK1 | |
| SCHEMBL22049393 | 0.73 | RAB9A (0.56) | RAB9ANPC1TRPV1PTGS1GSK3A | |
| SCHEMBL17894101 | 0.72 | PTGS1 (0.74) | RAB9ANPC1TRPV1PTGS1DEGS1 | |
| SCHEMBL30643217 | 0.72 | PTGS1 (0.74) | RAB9ANPC1TRPV1PTGS1DEGS1 | |
| SCHEMBL22049615 | 0.72 | RAB9A (0.55) | RAB9ANPC1TRPV1PTGS1GSK3A | |
| SCHEMBL3620154 | 0.71 | RAB9A (0.68) | RAB9ANPC1TRPV1PTGS1DEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2022140397-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140387-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140403-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140410-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2021-08-05 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236466-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | RAB9A 876/4885NPC1 859/4885TRPV1 631/4885 |
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | RAB9A 1457/4885NPC1 249/4885TRPV1 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.